Nishant Rastogi, MBA
Nishant Rastogi is a Vice President at New Rhein and a founding member of the firm’s Philadelphia office. Nishant shares responsibility for day-to-day operations, including identification and screening of new opportunities, due diligence, negotiation of deal structure, and portfolio company involvement. He currently serves as a Board Observer for Neuraptive Therapeutics and American Injectables, and helps manage the Fund’s investments in Butterfly Medical, Sayvaa Pharma, and Softhale.
Prior to joining New Rhein, Nishant was the first associate at Broadview Ventures. While at Broadview, he helped execute multiple transactions across medical device, pharmaceutical, and diagnostic technologies. In 2016, he contributed to a publication regarding the importance of impact investing in life sciences in the Journal of the American College of Cardiology.
Nishant has also held part-time investment roles in healthcare at Digitalis Ventures in New York, NY, and Linden Capital Partners in Chicago, IL. From 2012-2015, he worked in Corporate Strategy at Fidelity Investments. He holds an MBA from Northwestern University and a BA in Economics from Dartmouth College. He has also completed post-graduate coursework in medical sciences from Harvard University. Nishant was named one of Poets & Quants, “Top MBAs to Watch” in 2018. He is an avid Philadelphia sports fan, tennis player, and volunteer Board Member of The Spruce Foundation, a non-profit organization providing philanthropic grants in support of Philadelphia youth.